VANCOUVER, March 23, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is pleased to announce the appointment of Dr. Barry Waisglass as Medical Director.
Dr. Waisglass, a general practitioner, is one of Canada's most experienced physicians in the clinical use of medical cannabis and cannabinoids. As Aurora's Medical Director, his responsibilities include advising the Company with respect to emerging issues and opportunities with respect to medical cannabis, representing Aurora at Canadian and global medical and cannabis conferences, liaising with medical associations and colleges, participating in the development of new products and new delivery mechanisms, as well as supporting the Company's international market development initiatives.
Prior to his move to Aurora, Dr. Waisglass served as Medical Director for Canadian Cannabis Clinics and CanvasRx, the country's largest network of cannabis medical clinics and cannabis counseling centres. In this role, he provided training to other physicians, and treated patients affected by a wide range of health conditions, including chronic pain, fibromyalgia, mood disorders, spasticity caused by multiple sclerosis, chemotherapy-induced nausea, appetite disorders and epilepsy.
Dr. Waisglass, who received his degree in medicine from the University of Ottawa, has undergone additional professional training in psychotherapy and psychiatric medicine. He is currently a member of the College of Physicians and Surgeons of Ontario, the Canadian Medical Association, and the Ontario Medical Association.
"Barry is an important, strategic, and timely addition, as we expand our operations in Canada and internationally, and we are delighted that he is joining the Aurora team," said Terry Booth, CEO. "He is a deeply respected and widely-consulted clinical expert in the use of cannabis as medicine, and brings invaluable new insights and capabilities to our Company's exceptional management team."
Stock Options Grant to Directors
The Company has granted options to directors Terry Booth, CEO and Steve Dobler, President to purchase common shares of the Company in the aggregate amount of 2,500,000 (the "Options"). The Options will vest evenly on a quarterly basis over three years, and are exercisable for a period of five years at $2.27 per share.
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport. The Aurora Sky project has secured advanced technology from the most renowned design and construction suppliers in the Netherlands. Aurora's common shares trade on the TSX-V under the symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the Proposal will be completed on the terms or within the timeframe contemplated in this news release or at all. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.